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a b s t r a c t
The pathogenesis of autoimmune and neurodegenerative diseases involves overexpression of inducible
subunits of the immunoproteasome. However, the clinical application of inhibitors to inducible subunits
of the immunoproteasome has been limited due to systemic toxicity. Here, we designed siRNAs that
efﬁciently silence LMP2, LMP7 and MECL-1 gene expression. Inducible subunits of the immunoprotea-
some are complex siRNA targets because they have a long half-life; therefore, we introduced 20-O-methyl
modiﬁcations into nuclease-sensitive sites. This led to 90e95% silencing efﬁciency and prolonged
silencing, eliminating the need for multiple transfections. Furthermore, we showed that in the absence of
transfection reagent, siRNAs with lipophilic residues were able to penetrate cells more effectively and
decrease the expression of inducible immunoproteasome subunits by 35% after 5 days. These results
show that siRNA targeted to inducible immunoproteasome subunits have great potential for the
development of novel therapeutics for autoimmune and neurodegenerative diseases.
© 2016 Elsevier B.V. and Societe Française de Biochimie et Biologie Moleculaire (SFBBM). All rights
reserved.
1. Introduction
Proteasomes are large protein complexes that degrade mis-
folded proteins. This function is essential for many cellular pro-
cesses such as transcription, cell cycle progression, differentiation,
apoptosis, and the control of stress and immune responses [1,2].
The eukaryotic 26S proteasome consists of the multicatalytic 20S
core proteasome associated with regulatory complexes such as
PA700/19S or PA28/11S [3]. The 20S core proteasome is formed by a
and b subunits. Seven different, but related a subunits form two
outer rings, whereas seven different b subunits form two inner
rings. b1, b2 and b5 subunits exhibit proteolytic activity. The
constitutively expressed catalytic b subunits can be replaced by
inducible b immunosubunits and multicatalytic endopeptidase
complex-like 1 MECL-1 (b2i). Two inducible b immunosubunits are
lowmolecular weight protein LMP2 (b1i) and LMP7 (b5i). Together,
LMP2, LMP7 and MECL-1 form the immunoproteasome. b immu-
nosubunits are constitutively expressed in immune cells and in
other cells their expression is induced by inﬂammatory cytokines
such as interferon g (IFNg) [4e6].
The cleavage speciﬁcity of the immunoproteasome differs from
that of the constitutive proteasome. Compared with peptides pro-
duced by the constitutive proteasome, peptides produced by the
immunoproteasome can bind to MHC class I molecules more efﬁ-
ciently and facilitate a stronger adaptive immune response [7,8].
Recent studies revealed a connection between immunoproteasome
deregulation and the progression of neurodegenerative and auto-
immune diseases [9e12]. Increased expression of LMP2 and LMP7
immunosubunints was observed in all brain compartments of mice
with experimental autoimmune encephalomyelitis (EAE) [9].
Furthermore, immunosubunits LMP2 and MECl-1 were shown to
be markedly upregulated in Sj€ogren's syndrome [10]. Increased
expression of immunoproteasome subunits was also found in cases
of neurodegenerative diseases including Huntington's disease [11]
and Alzheimer's disease [12]. These observations support the role
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